165 related articles for article (PubMed ID: 17845754)
1. [KIT mutation analysis in pathological diagnosis and target-therapy of gastrointestinal stromal tumors: an update].
Chen LR
Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):440-3. PubMed ID: 17845754
[No Abstract] [Full Text] [Related]
2. [Molecular and histologic characteristics of secondary imatinib-resistant gastrointestinal stromal tumors].
Zheng S; Jia J; Pan YL; Tao DY; Lu HS
Zhonghua Bing Li Xue Za Zhi; 2013 Jan; 42(1):42-3. PubMed ID: 23611272
[No Abstract] [Full Text] [Related]
3. A hemodialysis patient with primary extra-gastrointestinal stromal tumor: favorable outcome with imatinib mesylate.
Wada Y; Ogata H; Misawa S; Shimada A; Kinugasa E
Intern Med; 2012; 51(12):1561-5. PubMed ID: 22728491
[TBL] [Abstract][Full Text] [Related]
4. [Consensus on the medical treatment of gastrointestinal stromal tumors].
Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):875-7. PubMed ID: 18396652
[No Abstract] [Full Text] [Related]
5. [Chemotherapy and target-therapy of gastrointestinal tumors call for development of pathology].
Shen L
Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):438-9. PubMed ID: 17845753
[No Abstract] [Full Text] [Related]
6. Response to imatinib in KIT- and PDGFRA-wild type gastrointestinal stromal associated with neurofibromatosis type 1.
Lee JL; Kim JY; Ryu MH; Kang HJ; Chang HM; Kim TW; Lee H; Park JH; Kim HC; Kim JS; Kang YK
Dig Dis Sci; 2006 Jun; 51(6):1043-6. PubMed ID: 16865565
[No Abstract] [Full Text] [Related]
7. Secondary resistance to imatinib mesylate in a patient with unresectable duodenal GIST without mutations in exons 9, 11, 13, or 17 of the c-kit protooncogene.
Yamaguchi M; Matsumoto T; Tate G; Higuchi T
J Gastroenterol; 2004 Sep; 39(9):904-5. PubMed ID: 15565413
[No Abstract] [Full Text] [Related]
8. [Chinese consensus in diagnosis and treatment of gastrointestinal stromal tumor].
Chinese Diagnosis and Treatment Experts Group for Gastrointestinal Stromal Tumors
Zhonghua Bing Li Xue Za Zhi; 2009 Oct; 38(10):697-702. PubMed ID: 20078976
[No Abstract] [Full Text] [Related]
9. Effect of imatinib mesylate in a patient with a metastatic gastrointestinal stromal tumor with a c-kit mutation in exon 11.
Kubota K; Katayama A; Takeshita Y; Nozaki K; Ueda T; Imamura K; Hiki N; Nomura S; Kaminishi M; Mafune K
Dig Dis Sci; 2007 Jul; 52(7):1725-9. PubMed ID: 17546507
[No Abstract] [Full Text] [Related]
10. [Gastrointestinal stromal tumor of small intestine associated with lymph node metastasis: a report of 2 cases with review of literatures].
Kong M; Wang YL; Xu LJ; Teng XD
Zhonghua Bing Li Xue Za Zhi; 2009 Sep; 38(9):617-20. PubMed ID: 20079191
[TBL] [Abstract][Full Text] [Related]
11. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations.
Wardelmann E; Thomas N; Merkelbach-Bruse S; Pauls K; Speidel N; Büttner R; Bihl H; Leutner CC; Heinicke T; Hohenberger P
Lancet Oncol; 2005 Apr; 6(4):249-51. PubMed ID: 15811621
[No Abstract] [Full Text] [Related]
12. [Study on the mechanism of imatinib-induced resistance in gastrointestinal stromal tumors].
Zhou Y; Hou YY; Tan YS; Lu SH; Hou J; Liu JL; Qin J; Shen KT; Sun YH
Zhonghua Zhong Liu Za Zhi; 2009 Aug; 31(8):597-601. PubMed ID: 20021947
[TBL] [Abstract][Full Text] [Related]
13. Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis.
Lee JH; Kim Y; Choi JW; Kim YS
J Gastrointestin Liver Dis; 2013 Dec; 22(4):413-8. PubMed ID: 24369323
[TBL] [Abstract][Full Text] [Related]
14. Advanced or metastatic gastrointestinal stromal tumors: systemic treatment options.
Caram MV; Schuetze SM
J Surg Oncol; 2011 Dec; 104(8):888-95. PubMed ID: 22069173
[TBL] [Abstract][Full Text] [Related]
15. Multidisciplinary treatment of gastrointestinal stromal tumors.
Kingham TP; DeMatteo RP
Surg Clin North Am; 2009 Feb; 89(1):217-33, x. PubMed ID: 19186237
[TBL] [Abstract][Full Text] [Related]
16. Clinical, histopathologic, molecular and therapeutic findings in a large kindred with gastrointestinal stromal tumor.
Kleinbaum EP; Lazar AJ; Tamborini E; Mcauliffe JC; Sylvestre PB; Sunnenberg TD; Strong L; Chen LL; Choi H; Benjamin RS; Zhang W; Trent JC
Int J Cancer; 2008 Feb; 122(3):711-8. PubMed ID: 17943734
[TBL] [Abstract][Full Text] [Related]
17. Imatinib resistance in gastrointestinal stromal tumors.
Chen LL; Sabripour M; Andtbacka RH; Patel SR; Feig BW; Macapinlac HA; Choi H; Wu EF; Frazier ML; Benjamin RS
Curr Oncol Rep; 2005 Jul; 7(4):293-9. PubMed ID: 15946589
[TBL] [Abstract][Full Text] [Related]
18. Recurrent gastrointestinal stromal tumor (GIST) of the stomach associated with a novel c-kit mutation after imatinib treatment.
Koyama T; Nimura H; Kobayashi K; Marushima H; Odaira H; Kashimura H; Mitsumori N; Yanaga K
Gastric Cancer; 2006; 9(3):235-9. PubMed ID: 16952044
[TBL] [Abstract][Full Text] [Related]
19. [Carney triad: clinicopathologic study of 2 cases with molecular analysis].
Xu C; Hou YY; Qi WD; Lu SH; Hou J; Tan YS; Qin J; Sun YH
Zhonghua Bing Li Xue Za Zhi; 2009 Sep; 38(9):626-7. PubMed ID: 20079194
[No Abstract] [Full Text] [Related]
20. Unlucky number 13? Differential effects of KIT exon 13 mutation in gastrointestinal stromal tumors.
McAuliffe JC; Wang WL; Pavan GM; Pricl S; Yang D; Chen SS; Lazar AJ; Pollock RE; Trent JC
Mol Oncol; 2008 Aug; 2(2):161-3. PubMed ID: 19383335
[No Abstract] [Full Text] [Related]
[Next] [New Search]
